Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.9894
- Book/Share 38.2151
- PB 8.1562
- Debt/Equity 0.5957
- CurrentRatio 0.7761
- ROIC 0.3599
- MktCap 1385478304840.9907
- FreeCF/Share 14.1116
- PFCF 22.0839
- PE 13.3532
- Debt/Assets 0.1976
- DivYield 0.0348
- ROE 0.6695
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | NVO | Jefferies | -- | Underperform | -- | -- | Oct. 27, 2025 |
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
News
EU drug regulator allows Novo Nordisk to include heart condition in Ozempic label
Published: June 23, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk said on Monday the European drugs regulator has adopted a positive opinion for an update of the Ozempic label to include peripheral artery disease.
Read More
Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic® (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.
Read More
Novo Nordisk Ends Partnership with Hims & Hers
Published: June 23, 2025 by: WSJ
Sentiment: Negative
The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations about Hims' compounding and deceptive marketing practices.
Read More
NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk's Mim8 shows strong safety and patient preference in the phase IIIb hemophilia A study switching from Hemlibra to Mim8.
Read More
Hims & Hers shares drop after Novo Nordisk ends Wegovy collaboration over compounding practices
Published: June 23, 2025 by: Proactive Investors
Sentiment: Negative
Shares of Hims & Hers Health (NYSE:HIMS) fell around 30% on Monday after Novo Nordisk (NYSE:NVO) terminated its collaboration with the telehealth company, citing violations related to compounding and marketing of the weight-loss drug Wegovy. Novo said it ended Hims & Hers' access to the FDA-approved treatment through its NovoCare platform, alleging that the company engaged in illegal mass compounding and deceptive marketing.
Read More
Novo Nordisk under pressure, ends deal with Hims & Hers
Published: June 23, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest details on the pharmaceutical space.
Read More
Novo Nordisk, Hims and Hers Shares Tumble on Severed Ties
Published: June 23, 2025 by: Schaeffers Research
Sentiment: Negative
Novo Nordisk A/S (NYSE:NVO) stock is down 5.3% to trade at $69.90 at last check, after the drugmaker's obesity drug CagriSema showed no clear advantage over Eli Lilly's (LLY) Zepbound.
Read More
Hims & Hers Stock Plunges as Novo Nordisk Abruptly Ends Partnership
Published: June 23, 2025 by: Barrons
Sentiment: Negative
Novo Nordisk accuses the telehealth company of breaking a law related to drug compounding.
Read More
Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%
Published: June 23, 2025 by: CNBC
Sentiment: Negative
Novo Nordisk said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company's sales and promotion of cheaper knock-offs of the weight loss drug Wegovy. Novo Nordisk in April said it would offer Wegovy through several telehealth companies, such as Hims & Hers, to expand access to the blockbuster injection now that it is no longer in short supply in the U.S.
Read More
Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral
Collaboration of over one month has ended based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy ® that put patient safety at risk Novo Nordisk won't stop taking action to protect Americans from the dangers of illicit foreign active pharmaceutical ingredients in knock-off drugs Efforts will continue to make authentic, FDA-approved Wegovy® directly available through NovoCare ® Pharmacy to select telehealth organizations that share our commitment to safe and effective medical treatment for patients living with chronic diseases PLAINSBORO, N.J. , June 23, 2025 /PRNewswire/ -- Novo Nordisk announced today that the company will …
Read More
Novo Nordisk ends collaboration with Hims & Hers over weight loss drug sale
Published: June 23, 2025 by: Reuters
Sentiment: Negative
Novo Nordisk said on Monday it would halt its collaboration with Hims & Hers Health over the sale of weight loss drugs.
Read More
Novo Nordisk's New Obesity Drug Beats Wegovy Weight Loss in Early Trial
Published: June 23, 2025 by: WSJ
Sentiment: Positive
Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.
Read More
Novo Nordisk shares fall as obesity pipeline faces investor scrutiny
Published: June 23, 2025 by: Reuters
Sentiment: Negative
Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema fuelled investor concerns about its competitiveness against rival Eli Lilly's pipeline.
Read More
Novo Nordisk's new obesity drug hits high efficacy marks, but investors stay cautious
Published: June 23, 2025 by: Proactive Investors
Sentiment: Neutral
Novo Nordisk (NYSE:NVO) delivered promising data over the weekend for its next-generation weight-loss injection, CagriSema, showing it can achieve weight reductions on par with the most effective treatments currently available. Yet the subdued market reaction on Monday suggests growing investor unease about how the Danish drugmaker will hold its lead in a rapidly crowding space.
Read More
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Higher dose of Wegovy ® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
Read More
Novo Nordisk's subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85 th Scientific Sessions in Chicago, US.1 Full results of two clinical trials evaluating the safety, tolerability and weight loss potential of subcutaneous and oral amycretin in people with overweight or obesity were published today in The Lancet medical journal.1,3 Amycretin is the first treatment that combines GLP-1 and amylin receptor agonism biology in a single molecule.
Read More
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (June 2025)
Published: June 20, 2025 by: 24/7 Wall Street
Sentiment: Negative
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Read More
Why Novo Nordisk (NVO) is a Great Dividend Stock Right Now
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?
Read More
Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market gains.
Read More
Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.
Read More
The Big 3: NVO, DIS, WHR
Published: June 13, 2025 by: Schwab Network
Sentiment: Positive
Andrew Arons joins today's Big 3 to talk about stocks he believes can make 20% moves over the next year. He sees Novo Nordisk (NVO) benefitting off a rising weight-loss drug trends, Walt Disney (DIS) excelling in its "experiences" sectors, and Whirlpool (WHR) gaining hedge fund interest as it recovers off a 52-week low.
Read More
NVO Stock up on Plans to Advance Obesity Candidate Amycretin
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for obesity, to phase III development.
Read More
Novo Nordisk plans to start late-stage trials for experimental obesity drug amycretin
Published: June 12, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first quarter of 2026 for adults who are overweight or obese.
Read More
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities following end-of-phase 2 interactions for subcutaneous and oral amycretin in weight management.
Read More
NVO Stock Gains After Parvus Asset Management Builds Stake
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline buzz.
Read More
Novo Nordisk: The Time To Buy Has Come
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Positive
Despite Novo Nordisk's recent stock slide, strong Q1 FY25 results and strategic initiatives reinforce a "Buy" rating, presenting a continued, albeit tested, investment opportunity for patient investors. Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market, despite revised guidance due to compounded drug impacts. NVO actively combats compounded GLP-1s via legal routes, new patient access programs like $499 Wegovy, and key formulary wins such as CVS exclusivity.
Read More
Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.
Read More
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406